[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 4 of about 4
1. Namasivayam S, Martin DR, Saini S: Imaging of liver metastases: MRI. Cancer Imaging; 2007;7:2-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific characterization of liver metastases in patients with primary non-hepatic tumors is crucial to avoid unnecessary diagnostic work-up for incidental benign liver lesions.
  • MR contrast agents provide critical tumor characterization and can be safely used in patients with iodine contrast allergy and renal failure.
  • Other agents, including newly developing gadolinium-chelates or iron oxide agents may provide additional benefits in selected applications.
  • The degree and nature of tumor vascularity form the basis for liver lesion characterization based on enhancement properties.
  • Neuroendocrine tumors including carcinoid and islet cell tumors, renal cell carcinoma, breast, melanoma, and thyroid carcinoma are tumors most commonly causing hypervascular hepatic metastases, which may develop early enhancement with variable degrees of washout and peripheral rim enhancement.
  • [MeSH-major] Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1995 Dec;165(6):1407-13 [7484575.001]
  • [Cites] Radiology. 1995 Aug;196(2):471-8 [7617863.001]
  • [Cites] Radiology. 1996 Mar;198(3):881-7 [8628887.001]
  • [Cites] Radiology. 1996 May;199(2):513-20 [8668804.001]
  • [Cites] Radiology. 1996 Jul;200(1):59-67 [8657946.001]
  • [Cites] Radiology. 1996 Sep;200(3):785-92 [8756932.001]
  • [Cites] J Magn Reson Imaging. 1996 Mar-Apr;6(2):291-4 [9132092.001]
  • [Cites] Eur Radiol. 1997;7(2):275-80 [9038130.001]
  • [Cites] Radiology. 1997 May;203(2):449-56 [9114103.001]
  • [Cites] Acta Radiol. 1997 Jul;38(4 Pt 2):626-30 [9245955.001]
  • [Cites] Acta Radiol. 1997 Jul;38(4 Pt 2):631-7 [9245956.001]
  • [Cites] Radiol Clin North Am. 1998 Mar;36(2):287-97 [9520982.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2005 May;13(2):241-54, v-vi [15935310.001]
  • [Cites] Radiol Clin North Am. 2005 Sep;43(5):861-86, viii [16098344.001]
  • [Cites] Cancer Imaging. 2005;5 Spec No A:S149-56 [16361131.001]
  • [Cites] AJR Am J Roentgenol. 2006 Apr;186(4):1051-8 [16554578.001]
  • [Cites] Radiology. 2006 Apr;239(1):122-30 [16493012.001]
  • [Cites] Eur Radiol. 2006 Jun;16(6):1337-45 [16453115.001]
  • [Cites] Cancer Imaging. 2006;6:33-42 [16766267.001]
  • [Cites] Eur Radiol. 2006 Sep;16(9):1898-905 [16691378.001]
  • [Cites] Radiology. 1999 Oct;213(1):86-91 [10540645.001]
  • [Cites] Radiology. 2000 Apr;215(1):89-94 [10751472.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2000 Nov;8(4):741-56 [11149677.001]
  • [Cites] Clin Liver Dis. 2002 Feb;6(1):73-90 [11933597.001]
  • [Cites] Clin Liver Dis. 2002 Feb;6(1):165-79, vii [11933587.001]
  • [Cites] AJR Am J Roentgenol. 1988 Jul;151(1):79-84 [3259825.001]
  • [Cites] Radiology. 1992 Jan;182(1):167-74 [1309218.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jan-Feb;17(1):67-74 [8419443.001]
  • [Cites] Radiology. 1994 Dec;193(3):657-63 [7972804.001]
  • [Cites] Radiology. 1995 Dec;197(3):575-7 [7480718.001]
  • (PMID = 17293303.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 31
  • [Other-IDs] NLM/ PMC1804118
  •  go-up   go-down


2. Canavese G, Azzoni C, Pizzi S, Corleto VD, Pasquali C, Davoli C, Crafa P, Delle Fave G, Bordi C: p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior. Hum Pathol; 2001 Oct;32(10):1094-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior.
  • The immunohistochemical expression of the inhibitors of cyclin-dependent kinases p21 and p27 was investigated in 109 endocrine tumors of the pancreas and gastrointestinal tract and compared with that of Ki67 and p53. p21 was found to be scarcely expressed without significant differences between benign and malignant or between differentiated and undifferentiated tumors.
  • Moreover, the protein may have a role in the resistance of differentiated endocrine tumors to chemotherapeutic agents. p27 high-expressor neoplasms were frequent in either benign (70.6%) or malignant (81.4%) differentiated tumors, thus not allowing the use of this protein for the differential diagnosis of malignant neoplasms as suggested for endocrine tumors of parathyroid and pituitary.
  • Classical midgut carcinoids were characterized by a sharp discrepancy between malignant behavior and very bland proliferative pattern, with Ki67 and p27 expressions similar to that of benign tumors.
  • [MeSH-major] Adenoma, Islet Cell / metabolism. Carcinoid Tumor / metabolism. Cell Cycle Proteins / metabolism. Gastrointestinal Neoplasms / metabolism. Pancreatic Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Cell Division. Cyclin-Dependent Kinase Inhibitor p21. Cyclin-Dependent Kinase Inhibitor p27. Cyclins / metabolism. Female. Gastrinoma / metabolism. Gastrinoma / pathology. Glucagonoma / metabolism. Glucagonoma / pathology. Humans. Immunohistochemistry. Insulinoma / metabolism. Insulinoma / pathology. Ki-67 Antigen / metabolism. Male. Middle Aged. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company
  • (PMID = 11679944.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


3. Huang H, Dong X, Gao SL, Wu YL: Conservative resection for benign tumors of the proximal pancreas. World J Gastroenterol; 2009 Aug 28;15(32):4044-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative resection for benign tumors of the proximal pancreas.
  • AIM: To evaluate the safety and long-term prognosis of conservative resection (CR) for benign or borderline tumor of the proximal pancreas.
  • METHODS: We retrospectively analyzed 20 patients who underwent CR at the Second Affiliated Hospital of Zhejiang University School of Medicine between April 2000 and October 2008.
  • RESULTS: The indications were: serous cystadenomas in eight patients, insulinomas in six, non-functional islet cell tumors in three and solid pseudopapillary tumors in three.
  • CONCLUSION: CR is a safe and effective procedure for patients with benign tumors in the proximal pancreas, with careful CCI-PJ and postoperative MCCL.
  • [MeSH-major] Pancreas / surgery. Pancreatectomy / instrumentation. Pancreatectomy / methods. Pancreatic Neoplasms / surgery. Pancreaticojejunostomy / instrumentation. Pancreaticojejunostomy / methods
  • [MeSH-minor] Adult. Aged. Cystadenoma, Serous / surgery. Female. Humans. Insulinoma / surgery. Islets of Langerhans / pathology. Islets of Langerhans / surgery. Male. Middle Aged. Pancreatic Fistula / surgery. Retrospective Studies. Surgical Procedures, Operative / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1995 Oct;222(4):580-8; discussion 588-92 [7574936.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):179-85 [7817989.001]
  • [Cites] Diabet Med. 1998 Jul;15(7):539-53 [9686693.001]
  • [Cites] J Gastrointest Surg. 1998 Nov-Dec;2(6):509-16; discussion 516-7 [10457309.001]
  • [Cites] Arch Surg. 2006 Mar;141(3):293-9 [16549696.001]
  • [Cites] J Gastrointest Surg. 2006 Jun;10(6):804-12 [16769536.001]
  • [Cites] Br J Surg. 2007 Oct;94(10):1254-9 [17583892.001]
  • [Cites] J Gastrointest Surg. 2007 Dec;11(12):1704-11 [17929105.001]
  • [Cites] Br J Surg. 2008 Jan;95(1):85-91 [18041022.001]
  • [Cites] Pancreas. 2008 Jan;36(1):44-9 [18192880.001]
  • [Cites] Br J Surg. 2000 Apr;87(4):434-8 [10759738.001]
  • [Cites] Ann Surg. 2000 Jun;231(6):890-8 [10816633.001]
  • [Cites] J Am Coll Surg. 2000 Jun;190(6):711-6 [10873007.001]
  • [Cites] Br J Surg. 2000 Jul;87(7):883-9 [10931023.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(5):466-72 [11180872.001]
  • [Cites] Surgery. 2002 Nov;132(5):836-43 [12464868.001]
  • [Cites] Dig Surg. 2003;20(6):506-10 [14506331.001]
  • [Cites] J Gastrointest Surg. 2004 Jul-Aug;8(5):532-8 [15239986.001]
  • [Cites] Ann Surg. 1976 Oct;184(4):403-13 [1015887.001]
  • [Cites] Surgery. 1984 Oct;96(4):608-16 [6435270.001]
  • [Cites] Surgery. 1993 May;113(5):532-5 [8488471.001]
  • [Cites] Ann Surg. 1993 Sep;218(3):229-37; discussion 237-8 [8103982.001]
  • [Cites] J Am Coll Surg. 1994 Nov;179(5):545-52 [7952456.001]
  • [Cites] Arch Surg. 1998 Mar;133(3):327-31 [9517749.001]
  • (PMID = 19705501.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2731956
  •  go-up   go-down


Advertisement
4. Pathak RD, Tran TH, Burshell AL: A case of dopamine agonists inhibiting pancreatic polypeptide secretion from an islet cell tumor. J Clin Endocrinol Metab; 2004 Feb;89(2):581-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of dopamine agonists inhibiting pancreatic polypeptide secretion from an islet cell tumor.
  • A patient with a large prolactinoma developed a metastatic islet cell tumor secreting pancreatic polypeptide.
  • Dopamine agonist drugs reduced the prolactin levels to normal, caused a 7-fold decrease in the pancreatic polypeptide levels, and inhibited the liver metastases.
  • The relatively benign risk profile of dopaminergic agents makes further testing of these drugs to treat neuroendocrine tumors a worthwhile endeavor.
  • [MeSH-major] Adenoma, Islet Cell / drug therapy. Adenoma, Islet Cell / metabolism. Bromocriptine / therapeutic use. Dopamine Agonists / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / metabolism. Pancreatic Polypeptide / antagonists & inhibitors
  • [MeSH-minor] Chromogranin A. Chromogranins / blood. Dose-Response Relationship, Drug. Female. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Neoplasms, Multiple Primary / metabolism. Prolactinoma / diagnosis. Prolactinoma / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14764765.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; 0 / Dopamine Agonists; 3A64E3G5ZO / Bromocriptine; 59763-91-6 / Pancreatic Polypeptide
  •  go-up   go-down






Advertisement